Matches in Wikidata for { <http://www.wikidata.org/entity/Q82659209> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- Q82659209 description "artículu científicu espublizáu en payares de 2011" @default.
- Q82659209 description "scientific article published on 23 November 2011" @default.
- Q82659209 description "wetenschappelijk artikel" @default.
- Q82659209 description "наукова стаття, опублікована в листопаді 2011" @default.
- Q82659209 name "Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer" @default.
- Q82659209 name "Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer" @default.
- Q82659209 type Item @default.
- Q82659209 label "Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer" @default.
- Q82659209 label "Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer" @default.
- Q82659209 prefLabel "Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer" @default.
- Q82659209 prefLabel "Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer" @default.
- Q82659209 P1433 Q82659209-3DCE02D9-FC71-450A-A1B8-1679469A00E4 @default.
- Q82659209 P1476 Q82659209-9C39B6DC-8FB3-41DC-9B5C-ACB4F6F300A7 @default.
- Q82659209 P2093 Q82659209-046DE289-700E-4FCC-B6A5-A8F07F787B81 @default.
- Q82659209 P2093 Q82659209-29293228-6D28-4869-AAAC-D8E490DC5CE0 @default.
- Q82659209 P2093 Q82659209-328EC1AD-F524-4EF1-BD7A-030AC4C5164B @default.
- Q82659209 P2093 Q82659209-47962672-C758-475F-87E9-BC0BEDC531DE @default.
- Q82659209 P2093 Q82659209-56FA4163-0960-45ED-B283-D8009BB8AD58 @default.
- Q82659209 P2093 Q82659209-75D7DC8B-13D8-42AC-BF84-0A208489F2C0 @default.
- Q82659209 P2093 Q82659209-94A4867B-DBD1-41ED-A099-CC02EB89B5E2 @default.
- Q82659209 P2093 Q82659209-A4C90B7C-55D5-4FE8-A930-7F412EA8D356 @default.
- Q82659209 P2093 Q82659209-ADF3AD3E-F975-4C63-8515-DCB4C02CA17C @default.
- Q82659209 P2093 Q82659209-BCEC8893-F1A3-4419-8C6E-5E25964EF4C7 @default.
- Q82659209 P2093 Q82659209-C1B69079-0BA7-4A80-AC8A-FCB2046F633E @default.
- Q82659209 P2093 Q82659209-C3DD0933-83AE-40EA-BB6C-C60CF9BF3886 @default.
- Q82659209 P2093 Q82659209-D3F14B37-9966-4BCF-A85C-5CAAC0641369 @default.
- Q82659209 P304 Q82659209-432A2070-CB05-422F-B32F-D2995B518C25 @default.
- Q82659209 P31 Q82659209-CBEEDE21-C4B3-4655-843F-9E2734CAE249 @default.
- Q82659209 P356 Q82659209-F7AC3AD5-74C6-4926-B0DC-9262F1F17DC9 @default.
- Q82659209 P433 Q82659209-64979D30-782D-44EF-876A-E3DFA9CA7052 @default.
- Q82659209 P478 Q82659209-D5339F76-F33B-4688-A269-6F45C2D0276F @default.
- Q82659209 P577 Q82659209-0A56FCB1-4E91-4B63-9BD8-A44BBE30B478 @default.
- Q82659209 P698 Q82659209-4FA5DAF0-5FA7-4F7C-8FCD-C9DEE75726A1 @default.
- Q82659209 P921 Q82659209-B448BCDF-FCAB-4C9D-BDD9-7C9A71E7E1BA @default.
- Q82659209 P921 Q82659209-D45AED6F-CB75-4236-8E64-81895193F9FE @default.
- Q82659209 P921 Q82659209-DF5336D3-FDF3-47AB-AD37-54FD71F3D4C4 @default.
- Q82659209 P921 Q82659209-F6A55280-DD46-4D35-8C9D-43DC17A3EE40 @default.
- Q82659209 P356 MDR555 @default.
- Q82659209 P698 22112969 @default.
- Q82659209 P1433 Q326122 @default.
- Q82659209 P1476 "Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer" @default.
- Q82659209 P2093 "B A Wood" @default.
- Q82659209 P2093 "G Sonpavde" @default.
- Q82659209 P2093 "J M Burke" @default.
- Q82659209 P2093 "J R Caton" @default.
- Q82659209 P2093 "J T Holmlund" @default.
- Q82659209 P2093 "L Leopold" @default.
- Q82659209 P2093 "M Brookes" @default.
- Q82659209 P2093 "M D Galsky" @default.
- Q82659209 P2093 "M T Fleming" @default.
- Q82659209 P2093 "P Karlov" @default.
- Q82659209 P2093 "T E Hutson" @default.
- Q82659209 P2093 "V Matveev" @default.
- Q82659209 P2093 "W R Berry" @default.
- Q82659209 P304 "1803-1808" @default.
- Q82659209 P31 Q13442814 @default.
- Q82659209 P356 "10.1093/ANNONC/MDR555" @default.
- Q82659209 P433 "7" @default.
- Q82659209 P478 "23" @default.
- Q82659209 P577 "2011-11-23T00:00:00Z" @default.
- Q82659209 P698 "22112969" @default.
- Q82659209 P921 Q181257 @default.
- Q82659209 P921 Q269829 @default.
- Q82659209 P921 Q420436 @default.
- Q82659209 P921 Q42824440 @default.